TheBrief.Health

FDA classified AVID Medical’s correction of convenience kits containing Huons sodium chloride ampules as Class I, prompting quarantine, exposure tracing, and patient assessment.

FDA approved atezolizumab plus chemotherapy after surgery for stage III mismatch-repair-deficient colon cancer, improving three-year disease-free survival and emphasizing biomarker confirmation.

FDA approved imlunestrant plus abemaciclib for ESR1-mutated advanced breast cancer after endocrine progression, making biomarker testing central to treatment selection and monitoring.

FDA classified the Bravo CF delivery-device recall as Class I, prompting facilities to quarantine affected inventory, review scheduled procedures, and arrange alternative reflux-monitoring options.

Tucatinib maintenance approval with trastuzumab and pertuzumab remains unverified in the supplied FDA source, requiring confirmation of eligibility, efficacy, safety, and prescribing guidance.

FDA classified Bravo CF delivery device removal as Class I after 184 serious injuries, prompting inventory verification, procedure reviews, patient assessment, and alternative reflux testing.

FDA classified the Impella introducer correction as Class I following serious bleeding complaints and deaths, prompting inventory checks, heightened hemorrhage vigilance, and reporting.

FDA warned of fungal contamination in certain IV-start kits, prompting facilities to quarantine affected products, trace patient exposures, and assess potential risks of invasive infection.

A randomized study found psilocybin-assisted therapy reduced treatment-resistant depression symptoms through six weeks, supporting further research while long-term durability, safety, and FDA approval remain unresolved.

FDA recalled six lots of compounded glutathione, Myers’ Cocktail, and Tri-Immune Boost injections over elevated endotoxin levels, prompting quarantine, exposure tracing, and clinical assessment.

A 2026 network meta-analysis found SGLT2 inhibitors more consistently reduced heart failure hospitalization, while mortality comparisons remained uncertain and empagliflozin’s arrhythmia signal requires confirmation.

FDA approved tiratricol for peripheral thyrotoxicosis in MCT8 deficiency, targeting excess T3 and cardiovascular effects without establishing reversal of neurological disability.

WHO’s pediatric sickle cell initiative emphasizes implementation, linking early screening, preventive treatment, referral, medicine access, and follow-up to improve equitable care for children.

Baxter recalled one cefazolin in dextrose injection lot over cardboard particles, prompting hospitals to quarantine affected inventory, maintain perioperative antibiotic coverage, and assess potential exposures.

ACHIEVE-5 found oral orforglipron added to titrated insulin glargine improved HbA1c and weight without increasing hypoglycemia, though numerical effect sizes and detailed safety findings remain important.

A randomized pediatric trial found ecopipam reduced Tourette syndrome tic severity versus placebo, supporting further investigation while long-term safety, comparative effectiveness, and FDA approval remain unresolved.

FDA classified the Luna G3 APAP firmware recall as Class I, urging clinics and suppliers to verify affected devices, coordinate corrections, and prevent therapy interruptions.

FDA approved camizestrant for eligible ESR1-mutated advanced breast cancer, enabling mutation-guided endocrine switching before radiographic progression while continuing CDK4/6 inhibitor therapy.

FDA classified Halyard IV START KIT NONSTERILE as Class I, prompting urgent inventory isolation, identifier verification, workflow protection, alternative supplies, and risk-based review of prior use.

FDA classified PiCardia’s ShortCut transfemoral catheter action as a Class 2 recall, prompting inventory checks, procedure planning updates, traceability, and review of prior device use.

FDA accelerated approval makes sevabertinib available for previously treated advanced nonsquamous NSCLC with qualifying HER2 mutations, emphasizing precise molecular testing and avoiding broad HER2 eligibility.

FDA approved lirafugratinib for previously treated advanced FGFR2-rearranged cholangiocarcinoma, making validated molecular testing essential for identifying eligible patients and guiding targeted treatment decisions after progression.

American Regent recalled a papaverine injection lot after particulate matter findings, prompting quarantine, inventory tracing, exposure assessment, symptom monitoring, and urgent evaluation for postexposure events.

FDA granted accelerated approval to sevabertinib for select HER2-mutated non-squamous NSCLC, requiring precise molecular eligibility while confirmatory studies establish clinical benefit.

ASTRUM-006 found serplulimab plus perioperative SOX improved event-free survival in PD-L1-selected resectable gastric or gastroesophageal junction cancer, supporting biomarker-guided investigation.